Nobivac Myxo-RHD Plus
myxomatosis and rabbit haemorrhagic viral disease vaccine (live recombinant)
Table of contents
Overview
Nobivac Myxo-RHD Plus is a vaccine used in rabbits to reduce death and clinical signs due to myxomatosis and rabbit haemorrhagic disease (RHD). Myxomatosis is caused by the myxoma virus and is spread between rabbits by close contact and biting insects such as fleas and mosquitoes. The virus causes swelling and discharge from the eyes, nose and bottom with most rabbits dying within 10 – 14 days. RHD, caused by classical RHD virus (RHDV1) and RHD type 2 virus (RHDV2), leads to blood clots in major organs such as the heart, lungs and kidneys leading to heart and respiratory failure when the heart and lungs do not work properly. Nobivac Myxo-RHD Plus contains live myxoma vectored RHD virus strains 009 and MK1899.
Authorisation details
Product details | |
---|---|
Name |
Nobivac Myxo-RHD Plus
|
Agency product number |
EMEA/V/C/004989
|
Active substance |
|
International non-proprietary name (INN) or common name |
myxomatosis and rabbit haemorrhagic viral disease vaccine (live recombinant)
|
Species |
Rabbits
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI08AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Date of issue of marketing authorisation valid throughout the European Union |
19/11/2019
|
Contact address |
Wim de Körverstraat 35 |
Product information
Nobivac Myxo-RHD Plus - EMEA/V/C/004989 - EMEA/V/C/004989
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for leporidae
Therapeutic indication
For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and rabbit haemorrhagic disease (RHD) caused by classical RHD virus (RHDV1) and RHD type 2 virus (RHDV2).